NCT00867607

Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis

A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 or steroid on the Treatment of Mild to Moderate Allergic Contact Dermatitis of the Hand and Forearm. Total number of patients: up to 80.

Conditions

• Allergic Contact Dermatitis

Interventions

Type	Name	Description
DRUG	MRX-6	b.i.d treatment for 21 days
DRUG	Steroid	b.i.d. 21 days

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-04-01
• Completion: 2014-03-01
• First posted: 2009-03-24
• Last updated: 2015-04-21

Locations

2 sites across 1 country: Israel